Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Oral Doses of CJ-12420 (Tegoprazan), A Novel Potassium-Competitive Acid Blocker (P-CAB) in Healthy Male Subjects

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Oral Doses of CJ-12420 (Tegoprazan), A Novel Potassium-Competitive Acid Blocker (P-CAB) in Healthy Male Subjects

The plasma concentrations of CJ-12420 and its metabolite, M1, were determined using a validated liquid chromatography-mass spectrometry method. The pharmacodynamic analysis of the SAD and MAD study showed rapid onset and dose-dependent gastric acid suppression.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical therapeutics 2017-08, Vol.39 (8), p.e97-e98
Hauptverfasser: Han, S, Choi, H. Youn, Kim, Y. Han, Nam, J. Yeon, Song, G. Seog, Lim, H.-S, Bae, K.-S
Format: Artikel
Sprache:eng
Schlagworte:
Acids
Gastroesophageal reflux
Internal Medicine
Liquid chromatography
Mass spectrometry
Mass spectroscopy
Medical Education
Pharmacodynamics
Pharmacokinetics
Pharmacology
Potassium
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The plasma concentrations of CJ-12420 and its metabolite, M1, were determined using a validated liquid chromatography-mass spectrometry method. The pharmacodynamic analysis of the SAD and MAD study showed rapid onset and dose-dependent gastric acid suppression.
ISSN:0149-2918
1879-114X
DOI:10.1016/j.clinthera.2017.05.306